Pharco D receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pharming Group NV (PHAR)
Pharming Group NV stock price live, this page displays AS PHAR stock exchange data. View the PHAR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Pharming Group NV real time stock price chart below.
What Is the Pharming Group NV Stock Price Today?
The Pharming Group NV stock price today is 1.477.
What Is the Stock Symbol for Pharming Group NV?
The stock symbol for Pharming Group NV is ""PHAR.""
What Stock Exchange Does Pharming Group NV Trade On?
Pharming Group NV is listed and trades on the Amsterdam stock exchange.
Is Pharming Group NV a Good Stock to Buy?
Determining whether Pharming Group NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHAR quote. (ISIN: NL0010391025) - Test -{{UPSIDE_OR_DOWNSIDE}} - {{DIVIDEND_YIELD}} - {{CURRENT_YEAR}}
What Is the Pharming Group NV Stock Price Today?
The Pharming Group NV stock price today is 1.477.
What Is the Stock Symbol for Pharming Group NV?
The stock symbol for Pharming Group NV is ""PHAR.""
What Stock Exchange Does Pharming Group NV Trade On?
Pharming Group NV is listed and trades on the Amsterdam stock exchange.
Is Pharming Group NV a Good Stock to Buy?
Determining whether Pharming Group NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHAR quote. (ISIN: NL0010391025) - Test -{{UPSIDE_OR_DOWNSIDE}} - {{DIVIDEND_YIELD}} - {{CURRENT_YEAR}}
Amsterdam
Currency in EUR
1.477
+0.018(+1.23%)
Closed·
Fair Value
An estimate of a Pharming Group's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.453
1.495
52 wk Range
0.686
1.818
PHAR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Pharming Group's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.4531.495
52 wk Range
0.6861.818
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PHAR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Pharming Group's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
2.214
Upside
+49.91%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
- Pharco D receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 6K Pharming Group NV For: 2 April
- Investing.com
- Form 6K Pharming Group NV For: 24 March
- Investing.com
- Pharco D receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 6K Pharming Group NV For: 2 April
- Investing.com
- Form 6K Pharming Group NV For: 24 March
- Investing.com
- Pharco D receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Pharming Group NV Earnings Call Summary for Q4/2025
- Pharming achieved first-ever profitability in 2025 with revenues of €376.1M, up 27% YoY; operating profit reached €26M vs. prior year loss.
- Stock fell 2.4% to €1.373 post-earnings despite 105% annual gain; market cap stands at $10.61B with InvestingPro rating stock as undervalued.
- Company guides mid-single-digit RUCONEST growth in 2026 with Q1 U.S. revenue pressured by inventory drawdowns; Joenja expected to grow 10+ points.
- Gross margin reached 88%; cash position of €181.1M supports operations amid regulatory challenges for Joenja's pediatric expansion in U.S.
- Key risks include HAE market competition affecting RUCONEST, regulatory hurdles for Joenja pediatric label, and potential supply chain disruptions.
Last Updated: 12/03/2026, 14:38
Read Full TranscriptCompare PHAR to Peers and Sector
Metrics to compare | PHAR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHARPeersSector | |
|---|---|---|---|---|
P/E Ratio | 429.1x | −4.0x | −0.4x | |
PEG Ratio | 3.51 | 0.00 | 0.00 | |
Price/Book | 4.4x | 4.1x | 2.6x | |
Price / LTM Sales | 3.3x | 4.5x | 3.2x | |
Upside (Analyst Target) | 48.0% | 98.9% | 51.4% | |
Fair Value Upside | Unlock | 18.8% | 6.7% | Unlock |
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 2.214
(+49.91% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
0.01 / --
Revenue / Forecast
97.3M / 98.22M
People Also Watch
FAQ
What Is the Pharming Group (PHAR) Stock Price Today?
The Pharming Group stock price today is 1.477 EUR.
What Stock Exchange Does Pharming Group Trade On?
Pharming Group is listed and trades on the Amsterdam Stock Exchange.
What Is the Stock Symbol for Pharming Group?
The stock symbol for Pharming Group is "PHAR."
What Is the Pharming Group Market Cap?
As of today, Pharming Group market cap is 1.040B EUR.
What Is Pharming Group's Earnings Per Share (TTM)?
The Pharming Group EPS (TTM) is 0.004.
When Is the Next Pharming Group Earnings Date?
Pharming Group will release its next earnings report on Nov 06, 2025.
From a Technical Analysis Perspective, Is PHAR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Pharming Group Stock Split?
Pharming Group has split 2 times.
How Many Employees Does Pharming Group Have?
Pharming Group has 407 employees.
What is the current trading status of Pharming Group (PHAR)?
As of Apr 12, 2026, Pharming Group (PHAR) is trading at a price of 1.477 EUR, with a previous close of 1.459 EUR. The stock has fluctuated within a day range of 1.453 EUR to 1.495 EUR, while its 52-week range spans from 0.686 EUR to 1.818 EUR.
What Is Pharming Group (PHAR) Price Target According to Analysts?
The average 12-month price target for Pharming Group is 2.214 EUR, with a high estimate of 2.5947099 EUR and a low estimate of 1.88651877 EUR. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +49.91% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.